.Attributes Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, patients along with metastatic intestinal lumps who got biomarker-matched therapies based upon spreading tumor DNA profiling revealed a better clinical advantage than those receiving unmatched therapy.